Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections

Fernando Echegaray1, Peter Laing2, Samantha Hernandez3, Sully Marquez4, Amanda Harris2, Ian Laing2, Adam Chambers5, Neil McLennan6, Victor A. Sugiharto7, Hua-Wei Chen7, Sandra Vivero Villagran8, Abigail Collingwood9, Magelda Montoya3, Fausto Bustos Carrillo3, Mark P. Simons7, Philip J. Cooper10,11, Andrea Lopez11, Gabriel Trueba4, Joseph Eisenberg9, Shuenn-Jue Wu7, William Messer12, Eva Harris3, Josefina Coloma3 and Leah C. Katzelnick1*

1 Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States, 2 Excivion Ltd., Cambridge, United Kingdom, 3 Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States, 4 Instituto de Microbiologia, Universidad San Francisco de Quito, Quito, Ecuador, 5 Oxford Expression Technologies Ltd., Oxford, United Kingdom, 6 GlobalDX Ltd., Mensrie, United Kingdom, 7 Viral & Rickettsial Diseases Department, Naval Medical Research Center, Silver Spring, MD, United States, 8 Instituto de Investigación en Biomedicina (Inbiomed), Universidad Central, Quito, Ecuador, 9 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, United States, 10 Department of Infection and Immunity, St George’s University of London, London, United Kingdom, 11 School of Medicine, Universidad Internacional del Ecuador, Quito, Ecuador, 12 Department of Molecular Microbiology and Immunology, Oregon Health and Sciences University, Portland, OR, United States

The only licensed dengue vaccine, Dengvaxia®, increases risk of severe dengue when given to individuals without prior dengue virus (DENV) infection but is protective against future disease in those with prior DENV immunity. The World Health Organization has recommended using rapid diagnostic tests (RDT) to determine history of prior DENV infection and suitability for vaccination. Dengue experts recommend that these assays be highly specific (≥98%) to avoid erroneously vaccinating individuals without prior DENV infection, as well as be sensitive enough (≥95%) to detect individuals with a single prior DENV infection. We evaluated one existing and two newly developed anti-flavivirus RDTs using samples collected >6 months post-infection from individuals in non-endemic and DENV and ZIKV endemic areas. We first evaluated the IgG component of the SD BIOLINE Dengue IgG/IgM RDT, which was developed to assist in confirming acute/recent DENV infections (n=93 samples). When evaluated following the manufacturer’s instructions, the SD BIOLINE Dengue RDT had 100% specificity for both non-endemic and endemic samples but low sensitivity for detecting DENV seropositivity (0% non-endemic, 41% endemic). Sensitivity increased (53% non-endemic, 98% endemic) when tests were allowed to run beyond manufacturer recommendations (0.5 up to 3 hours), but specificity decreased in endemic samples (36%). When tests were evaluated using a quantitative reader, optimal specificity could be achieved (≥98%) while still retaining sensitivity at earlier timepoints in non-endemic (44-88%) and endemic samples (31-55%). We next evaluated novel dengue and Zika RDTs developed by Excivion to detect...
INTRODUCTION

Dengue viruses 1 to 4 (DENV1-4) are mosquito-borne flaviviruses that cause about 105 million infections globally each year (1). Approximately 25% of DENV infections cause symptomatic febrile episodes and ~500,000 result in hospitalizations annually (1–4). DENV1-4 are considered serotypes (5). Primary infection with one DENV serotype induces long-term immunological protection against that specific serotype but can increase the risk of developing severe dengue disease during secondary infection by one of the other three serotypes (6, 7). However, after recovering from a secondary DENV infection, individuals are much less likely to develop severe dengue disease upon subsequent infection (8). This has led researchers to conclude that having sequential DENV infections with two distinct serotypes can induce enduring immunological cross-protection against all four DENV serotypes (9).

The only licensed dengue vaccine, Dengvaxia® (Sanofi Pasteur, Lyon, France), also was shown to provide protection against future disease in children vaccinated after they have had at least one prior DENV infection (10). However, Dengvaxia® increased the risk of severe breakthrough DENV infections in children vaccinated when seronegative (10). For this reason, in 2018 the Strategic Advisory Group of Experts on Immunization for the World Health Organization (WHO) recommended using serological assays, such as rapid diagnostic tests (RDT), to provide evidence of prior DENV infection and suitability for vaccination (11). Individuals identified as DENV-seropositive by such assays would be eligible for vaccination while those identified as DENV-seronegative would not. In response, in 2019 the Global Dengue and Aedes-transmitted diseases Consortium (GDAC) recommended that assays have optimal specificity (≥98%) and sensitivity (≥95%) when used for this purpose, with a minimum specificity and sensitivity of 90% (12).

When testing for DENV serostatus, “specificity” refers to the ability of a test to accurately identify those who are truly DENV-naïve as negative. In the context of dengue pre-vaccination screening, high specificity is required to avoid vaccinating individuals who are truly naïve and putting them at risk (12, 13). Conversely, “sensitivity” refers to the ability of that test to accurately identify those who have had a prior DENV infection as positive. High sensitivity in dengue pre-vaccination screening assays maximizes detection of individuals with a single prior DENV infection who would benefit from vaccination because they are at greater risk for developing severe dengue disease (6). In 2019, Sanofi Pasteur, the developer of Dengvaxia®, evaluated the specificity and sensitivity of four dengue RDTs (Bio-Rad DENGUE DENGUE IgA/IgG, CTK Biotech OnSite Dengue IgG/IgM, SD BIOLINE Dengue IgM/IgG, and GenBody Dengue IgG/IgM) and observed high specificity overall (≥98%) but lower sensitivities (40–70%) (14). Further, all four dengue RDTs failed to detect antibodies in individuals with DENV neutralizing antibody titers of <1:100, the group at greatest risk for future severe dengue (6). Sensitivity was also low (0-32%) for sera from individuals with DENV neutralizing antibody titers of 1:100-1:500 (14).

Moreover, the performance of a given RDT varies depending on the setting in which it is being used. Dengvaxia is recommended for individuals age 9 years and above, primarily in endemic areas. If information about seroprevalence in the target population is available, measuring the probability that a positive test result is truly positive (positive predictive value, PPV), and a negative test result is truly negative (negative predictive value, NPV), can aid in determining acceptable levels of misclassification (12, 13). In 2019, the GDAC recommended RDTs have a PPV and NPV of ≥95%, with a minimum of ≥90% (12). Using samples that are reflective of the settings in which the RDT will be used is important when calibrating RDT positivity cutoff values.

Another challenge for the diagnostic performance of dengue RDTs is the target antigen: most dengue RDTs use DENV1-4 recombinant envelope (E) protein, a primary target for neutralizing antibodies. However, antibodies targeting the E protein are highly cross-reactive, especially those targeting the fusion loop, which is both immunodominant and highly conserved across flaviviruses (15, 16). In the evaluation by Sanofi Pasteur, cross-reactivity in dengue RDTs was observed for individuals with prior Zika virus (ZIKV) infection (14). Given the structural and antigenic similarity of DENV and ZIKV, their co-circulation in Asia, Africa, and the Americas, and the recent ZIKV pandemic in 2014-2017, dengue RDT cross-reactivity for ZIKV-positive samples is of concern (16). More importantly, since it is unknown whether individuals with a single prior ZIKV
infection and no prior DENV infection will benefit from or be harmed by vaccination with Dengvaxia®, for the time being these individuals must be excluded from vaccination (17).

In this study, we evaluated a commonly used dengue RDT (SD BIOLINE Dengue IgG/IgM) and report for the first time the evaluation of new dengue and Zika RDTs developed by Excivion, which use a modified E antigen to distinguish previous DENV and ZIKV immunity. Further, we tested the effect of modifying various assay parameters to potentially improve performance for dengue pre-vaccination screening. We found quantitative evaluation can improve RDT performance, especially for the Excivion Zika RDT, but the SD BIOLINE Dengue IgG/IgM and Excivion Dengue RDT still require further development to be used as optimal dengue pre-vaccination screening assays.

METHODS

SD BIOLINE Dengue IgG/IgM RDT

Test Design and Architecture

The SD BIOLINE Dengue IgG/IgM RDT (Bitodiagnostico, Quito, Ecuador) detects anti-DENV E protein-specific IgG and IgM antibodies in serum or plasma. Sample anti-DENV IgG and IgM antibodies form a complex with recombinant DENV1-4 E proteins conjugated with a colloidal gold marker. As Ig-DENV E complexes move along the strip, they are captured by a corresponding mouse monoclonal anti-human IgG or IgM antibody (G or M line). Rabbit anti-DENV IgG are positioned at the control (C) line to confirm viability of gold marked DENV E proteins.

Clinical Samples and Ethical Statements

The IgG component of the SD BIOLINE Dengue IgG/IgM RDT was evaluated using samples from two cohorts. Blood samples (n=24) collected 1-30 years following confirmed DENV and/or ZIKV infection were provided by adults (age 18-93 years) recruited in Portland, Oregon with histories of travel to dengue-endemic areas (Table 1). Infection histories were confirmed by RT-PCR and/or focus reduction neutralization test (FRNT), as described previously (18). Signed consent was obtained from subjects prior to sample and data collection under a protocol approved by the Oregon Health & Science University Institutional Review Board (IRB) (IRB# 10212). In a separate study, serum samples (n=69) were provided by participants in the EcoDess cohort in Borbón, Ecuador (Table 1). Participants ranged in age from 2-60 years old, with an even proportion of individuals of each sex. Samples were collected in October 2018, ~four months after the high DENV transmission season. DENV seroprevalence in this population was estimated to be 64%. DENV serostatus was measured using the Dengue PanBio IgG ELISA, using cutoff values established by DENV1-4 PRNT titers: DENV-naïve (<0.2 units), DENV-primary (0.2-0.9) and DENV-secondary (>0.9) (19). ZIKV serostatus was measured with the gold-standard ZIKV non-structural protein 1 blockade-of-binding assay (inhibition ≥50% was defined as positive) (20). The IRBs of the University of Michigan and the Universidad San Francisco de Quito approved the EcoDess Study. All individuals over age 18 provided informed consent. Parents provided informed consent for children under age 18, and all children age 6 and older also provided oral assent.

Test Evaluation and Data Collection

The SD BIOLINE Dengue IgG/IgM RDT was used as recommended by the manufacturer. Images were collected of the RDT strip at 0.25, 0.5, 0.75, 1, 1.5, 2, and 3 hours using a standardized light source with an iPhone 6 camera positioned 15 cm above each test. IgG band positivity was evaluated visually by having independent analysts classify RDT results as negative (0), ambiguous (0.5), and positive (1). For the Oregon cohort, each sample was tested in two independent experiments, and a blinded analyst evaluated all images. For the EcoDess cohort, three independent, blinded analysts evaluated each image. We report average consensus values across analysts (values >0.5 are positive). Quantitative IgG band pixel intensity was measured from images using the EBImage package in R (21). Background pixel intensity of the RDT strip was subtracted from the IgG band. Higher values indicate stronger signal.

Excivion Dengue RDT and Zika RDT

Test Design and Architecture

DENV1-4 and ZIKV E proteins were engineered to contain a sequence-programmed N-linked glycosylation of the fusion loop (US Patent Application No.16/303,588) (Figure 1). The baculovirus-expressed fusion-loop hyperglycosylated exodomain E antigens (abbreviated FL-glycosylated E) were produced in Tni cells (US Patent Application No. 16/615,788). The primary DENV1-4 and ZIKV FL-glycosylated E antigen targets contained a C-terminally located hexahistidine tag to allow arrest at a line of monoclonal anti-His-tag antibody on the nitrocellulose test strip. The sample pad additionally contained an excess amount of non-His-tagged FL-glycosylated DENV or ZIKV E antigen to adsorb out residual cross-reactive antibodies directed at sites other than the fusion loop and block a false signal.

To construct each RDT, nitrocellulose (MDI Advance Microdevices, grade 150CNP-N-SS40) was laminated onto 250 mm adhesive backing card (Lohmann) and stripped with 0.3 mg/mL ReadyTag anti-6 His (BioXcell, cat. no. RT0266) as the test line and 1 mg/mL human IgG (Sigma-Aldrich, cat. no. 18640) with acid blue dye as the control line. The conjugate pad (Ahlstrom, grade 6615) was pre-treated in a solution containing 0.1 M Tris-HCl, pH 8.0, 0.5% bovine serum albumin and 0.25% Tween-20. Gold colloidal (40 nm, BBI Solutions) was conjugated to anti-human IgG Mab (Eastcoast Bio, cat. no. HM295) at 3.5 μg/mL in 25 mM borate buffer, pH 9.0 followed by blocking by adding 10% bovine serum albumin in water at a final concentration of 0.5%. After washing and centrifugation the gold conjugate was resuspended to give an effective concentration of 10 gold units per microliter. The conjugate was sprayed using a nebulizer onto the previously prepared and dried conjugate pad so that there were 3.5 μL gold conjugate per test. For the DENV RDT, the sample pad (Ahlstrom, grade 8951) was stripped with His-tagged DENV1-4 FL-glycosylated E antigens (25 ng of each per test) and and Strep-tag II ZIKV FL-glycosylated E antigen (1 μg per test) in PBS buffer (Sigma-Aldrich, cat. no. P4417) as a single line at 0.5 μl/mm. For the ZIKV RDT, the sample pad was stripped with His-tagged ZIKV FL-glycosylated E.
antigen (50 ng per test) and Strep-tag-II DENV2 FL-glycosylated E antigen (10 µg per test) in PBS buffer at 1.5 µl/mm. In both RDTs, acid blue dye was added to the solution at 0.5% to facilitate visualization of the striping procedure. An absorbent pad (Whatman, CF5) was laminated to the distal end of the backing card with a 1-2 mm overlap with the previously laminated nitrocellulose. The gold-coated conjugate pad was laminated proximal to the nitrocellulose with a 1-2 mm overlap, and finally the antigen striped sample pad was positioned upstream of the conjugate pad with a 1-2 mm overlap. The fully laminated 250 mm cards were cut into 5 mm individual test strips using a Kinematic cutter and then assembled into plastic lateral flow cassettes. Tests were packaged in a foil pouch containing cassettes, desiccant, and a separate squeeze bottle of buffer and stored at 4° C in the dark until used.

Clinical Samples and Ethical Statements
The Excivion Dengue RDT was initially evaluated using samples from acute/convalescent confirmed dengue cases and recent infections. The first set of acute and early convalescent (days 1-21 post-symptom onset) deidentified clinical samples were used by the Naval Infectious Diseases Diagnostic Laboratory at the Naval Medical Research Center, and included samples provided by Naval Medical Research Unit Two (NAMRU-2) (Phnom Penh, Cambodia) and the Naval Medical Research Unit Six (NAMRU-6) (Lima, Peru) under approved human use protocol #: PJT-17-06 (Table 1). Past infection history and/or serostatus was determined by CDC Trioplex real-time RT-PCR and dengue IgM and IgG ELISAs. ELISA-positive samples were tested using the CDC dengue PRNT against DENV2, DENV3, and DENV4 (positive defined as PRNT₉₀ titer of ≥10) or DENV
DENV infections or con-infection was evaluated based on the number of observed prior infection events. Primary versus secondary DENV classification was done upon disease presentation (27). All subsequent DENV and ZIKV infections (25, 26). In the hospital-based study, children enrolled upon disease presentation (27). All subsequent DENV and ZIKV infections could be determined (17, 23, 24). Children in the community-based cohort were followed longitudinally as they experience their first and subsequent DENV and ZIKV infections (25, 26). In the hospital-based study, children enroll upon disease presentation (27). All samples were collected 6-12 months post-infection. Infecting virus was confirmed by RT-PCR, virus isolation, or a serological algorithm for the small subset of PCR-negative cases (23). DENV serostatus and ZIKV infections were measured in paired annual samples using the Abcam Human Anti-Dengue virus IgG ELISA Kit (ab108728). ZIKV serostatus was measured using the Abcam anti-Zika virus IgG ELISA kit (ab221844) and the anti-Zika virus IgM ELISA kit (μ-capture) (ab213327) (Abcam, Cambridge, UK). None of the samples collected before the emergence of Zika were ZIKV-IgG positive. The IRBs of the Hospital Pedro Vicente Maldonado and the Universidad San Francisco de Quito approved the study protocol. Informed written consent was obtained from a parent and minor assent from the child.

### Test Procedure and Data Collection

Serum/plasma (5 µL) was added to the sample port and incubated 1-5 minutes at room temperature. Tests were chased with 120 µL of running buffer containing PBS, 0.025% Tween-20 and 0.5% polyethylene glycol, 20K (Sigma-Aldrich). All tests were run at room temperature for 0.5 hours before visual and quantitative data collection. For the Nicaragua samples, images of the test strip were also collected using the iPhone 6 by 1-3

![FIGURE 1](image-url) | Sequence alignment of the highly conserved fusion loop region of the E proteins for distinct flaviviruses compared to the Excivion DENV1-4 and ZIKV fusion loop-glycosylated antigens. (A) Sequence homology between ZIKV, DENV1-4, West Nile virus, Japanese encephalitis virus, and yellow fever virus as previously described (15). Sequences of DENV1-4 (B) and ZIKV (C) used for the Excivion Dengue and Zika RDTs, with position of the N-linked glycosylation sequon boxed in black.
operators and IgG band intensity was also measured at 0.75 and 1 hours. To evaluate reproducibility for the Nicaragua samples, 10 samples were run independently in separate tests and a subset of tests was measured twice using the ChemBio Cube portable lateral flow test reader.

**Test Evaluation and Data Collection**

Qualitative IgG band positivity was evaluated independently by SeraCare Life Sciences (now LGC) for the Dengue Mixed Titer Accuset™ Performance Panel. For the NMRC samples, the tests were performed and evaluated blindly in duplicate by two independent operators. Discrepancy in result interpretation was resolved using a third independent observer. Analysts assigned band intensity according to a scale from 0-5 (0= no band to 5= very strong band). The average value is reported. For the Nicaragua samples, one operator conducted all tests. Two independent analysts qualitatively evaluated IgG band positivity, with each reporting a value of 0 for negative, 0.5 for ambiguous, and 1 for a positive test result. The average value was reported and values >0.5 were considered positive and ≤0.5 as negative. Quantitative IgG band positivity for the ECUAVIDA and Nicaragua study samples was calculated using the ChemBio Cube portable lateral flow test reader. Higher values indicate stronger signal.

**Data Visualization and Statistical Analyses**

Individual samples were grouped by shared DENV and ZIKV infection histories based on the reference and/or gold-standard assays used for each cohort. All individual datapoints are plotted, with median and interquartile range intervals presented as summary statistics. Sensitivity and specificity were calculated by comparing all DENV-seronegative samples (including primary ZIKV) to all DENV-seropositive samples. For some cohorts, we performed a secondary analysis comparing all DENV-negative samples only to primary DENV-positive samples. Sensitivity and specificity for visual measures of IgG band positivity were evaluated using contingency tables in GraphPad Prism 8 software. P-values and statistical significances were computed using Fisher’s exact test. For quantitative measures of IgG band positivity, pixel intensity positivity cutoff values and confidence intervals were derived using receiver-operating characteristic (ROC) curves using the hybrid Wilson/Brown method at each timepoint using R and Prism. Pixel intensity positivity cutoff values were then selected according to the GDAC optimal (≥98%) or minimum (≥90%) specificity (12). All sensitivity and specificity values at each timepoint were plotted in Prism and fit curves were generated using smoothing spline curves or simple linear regression when ≤3 timepoints were analyzed. PPV and NPV were calculated using the seroprevalence estimates for the corresponding age group and time of collection of samples in each cohort.

**RESULTS**

**SD BIOLINE Dengue IgG/IgM RDT**

We first evaluated the performance of the SD BIOLINE Dengue IgG/IgM RDT to detect prior DENV infections in travelers recruited in Portland, Oregon who experienced virologically (RT-PCR) and/or serologically (FRNT) confirmed DENV and ZIKV infections while traveling to an endemic area. Serum from DENV-naïve individuals who had not visited endemic areas were also tested. The RDT was performed as recommended by the manufacturer, with test positivity evaluated visually at 0.25 hours. We found that the 5 DENV-negative individuals (2 yellow fever vaccinee recipients and 3 individuals with one prior ZIKV infection, ZIKV+) were consistently negative (Figure 2A), yielding a test specificity of 100%. However, none (0/16) of the individuals with history of one (DENV+ primary) or multiple prior DENV infections (DENV+ secondary) were detected by the SD BIOLINE Dengue IgG/IgM RDT, yielding a sensitivity of 0% (Figure 2B).

In preliminary analyses using control sera, we had observed that the IgG line turned positive in some samples when tests were allowed to run for longer than recommended. We tested the hypothesis that detection of historical DENV infections would improve with time by reading the test at serial intervals of 0.25, 0.5, 0.75, 1, 1.5, 2, and 3 hours. All DENV-negative samples remained negative at all timepoints (specificity: 100%) (Figure 2A). However, even at later timepoints, only a subset of DENV+ primary samples (5/12) were positive, with differences in positivity by serotype (lower for DENV1 and DENV4 than DENV2 and DENV3, Figure S1). Sensitivity for this group was 0% between 0.25 and 1.5 hours and only reached 42% when tests were read at 3 hours (Figure 2B). Overall, sensitivity including all DENV-positive samples increased at later timepoints but only reached 53% percent by 3 hours (Figure 2B).

As an alternative approach to improve dengue RDT performance, we tested whether measuring IgG intensity quantitatively would enable identification of optimal cutoff values for distinguishing positive from negative samples. Band pixel intensity was measured from images of the test strip using R. Using this approach, DENV-negative samples maintained lower band intensity values overall, whereas we detected a continuous increase in band intensity over time for samples with a history of DENV infection (Figures 2C, D). Quantitative evaluation enables selecting positivity cutoff values based on assay performance criteria, and for dengue pre-vaccination screening, specificity should be prioritized. Thus, we evaluated sensitivity after setting the specificity according to the GDAC recommended optimum (≥98%) and minimum (≥90%). (In this instance, the only specificity ≥90% was 100% and thus the same value is shown for both specificity cutoffs.) Using this approach, for both specificity levels, sensitivity was much higher at early timepoints (44% at 0.25 hours, 88% at 0.5 hours, 81% at 0.75 hours) than when evaluated visually (0%) (Figure 2D vs. 2B). Although still below the desired sensitivity of 95% proposed by GDAC, this demonstrates the potential benefit of using quantitative readers to maximize detection of DENV-positive individuals.

To evaluate the performance of the SD BIOLINE IgG/IgM RDT in a DENV and ZIKV-endemic setting, we tested healthy samples collected during the low-DENV transmission season from 69 individuals ages 2-60 participating in a dengue and Zika cohort study in Esmeraldas, Ecuador. Given that no gold-standard was available, DENV serostatus was determined using the PanBio DENV IgG ELISA using cutoff values established for
this assay using the FRNT as previously described (19). ZIKV serostatus was defined using the ZIKV NS1 BOB assay, an assay that has been extensively evaluated and is highly specific (20).

When each RDT was evaluated visually, DENV-seronegative samples (n=25) were negative at earlier timepoints but became ambiguous after 1-2 hours (Figure 3A), with specificity dropping from 100% at 0.25-0.5 hours to 80% at 1 hour. DENV-seropositive samples (n=44) became more positive over time (Figure 3B), with sensitivity of 41% at 0.25 hours (primary only: 16%) but reaching 96% when read at 1 hour (primary only: 79%). When instead the RDT was evaluated quantitatively, specificity values could be maintained at the levels recommended by GDAC (≥98% and ≥90%) while sensitivity at 0.25 hours remained high (57% and 70%, respectively) (Figures 3C, D). Sensitivity varied with time beyond 0.25 hours but was relatively stable and above 55% when using the minimum specificity ≥90%.

Because this cohort is based in an endemic area where dengue vaccines might be used, we were also able to consider the performance of the assay with respect to local seroprevalence, which was used to estimate PPV and NPV. The PPV was 100% at ≥98% specificity and was 92% at ≥90% specificity, reaching the optimal 95% at 1.5 and 3 hours (Figure S2-A). NPV was higher
when using optimal specificity (≥98%) and peaked at 1 hour (87%) but never reached the minimum of 90%, as recommended by GDAC. Overall, when tests were evaluated visually, sensitivity increased with time at the expense of specificity, limiting reading of the RDT to earlier timepoints. Quantitative evaluation enabled the tests to reach recommended specificity and PPV, while also improving sensitivity and NPV.

**Excivion Dengue RDT**

Other flaviviruses can induce antibodies that target the conserved E protein fusion loop and result in false positive dengue RDT results. Such cross reactivity became an urgent concern after the Zika epidemic, given the close antigenic relatedness of DENV and ZIKV (16). To address the need for a dengue RDT that sensitively and specifically detects remote prior DENV infection for use in a mass dengue vaccination campaign, Excivion developed a novel lateral flow dengue RDT using DENV1-4 E proteins in which two asparagine-linked glycans were inserted into E fusion loop without disrupting the overall structure of the E protein, leaving other E epitopes accessible. Further modifications were made to the test design to overcome cross-reactivity, including incorporation of excess glycan-blocked ZIKV E protein to preabsorb cross-reactive antibodies to epitopes outside the fusion loop. We first evaluated how the Excivion Dengue RDT performed as a standard diagnostic assay using acute and convalescent samples from confirmed dengue and Zika cases (1-21 days post symptom onset) tested at the Naval Infectious Diseases Diagnostic Laboratory at the Naval Medical Center. Infections were confirmed by RT-PCR and IgM and IgG ELISA. All ELISA-positive samples were further tested using either the
CDC PRNT against DENV2, DENV3, and DENV4 (positive: PRNT90 titer of ≥10) or DENV microneutralization tests. None of the 12 DENV-negative samples were positive by the Excivion Dengue RDT, yielding a specificity of 100%. Notably, 3 primary ZIKV infection samples, which were negative by DENV neutralization test, were also negative in the Excivion Dengue RDT. Further, the Excivion dengue RDT detected 17 out of 18 DENV-positive samples for an overall sensitivity of 94% (Table 2). The performance of the Excivion dengue RDT was then independently compared to other dengue IgG ELISAs and RDTs using the SeraCare Dengue Mixed Titer Accuset™ Performance Panel (n=11). The Excivion dengue RDT had higher sensitivity (100%) for detecting samples likely to have had recent (IgM and IgG) or historic (IgG only) DENV infections compared to the SD BIOLINE Dengue Duo RDT (18%) and the PanBio IgG RDT (9%) (Table 3). Further, the Excivion dengue RDT was as sensitive for detecting DENV-seropositive samples as five commercially available DENV IgG ELISAs (Table 3).

We performed a full evaluation of the Excivion Dengue RDT using samples collected six or more months after confirmed DENV and ZIKV infections from children participating in pediatric cohort and hospital studies in Managua, Nicaragua. Dengue and Zika cases were confirmed by RT-PCR and/or virus isolation, with a subset confirmed by serological algorithm. Inapparent DENV and ZIKV infections were confirmed by DENV and ZIKV iELISA, DENV neutralization assay, and/or ZIKV NS1 BOB on paired annual samples. Most samples were from children with primary DENV and ZIKV infections (n=32), the most difficult samples to classify. When evaluated visually at 0.5 hours, 3/5 DENV-naïve and 12/14 primary ZIKV infection samples were negative by the Excivion Dengue RDT, with a total specificity of 79% (Figure 4A). Additionally, 12/18 primary DENV samples were positive (sensitivity of 67%) and 14/15 secondary DENV infection samples were positive, for a total sensitivity of 79% (Figure 4B). Sensitivity also differed by serotype, with the highest sensitivity for DENV2 (Figure S3).

When the Excivion Dengue RDT was evaluated quantitatively and specificity was set to ≥98%, sensitivity reached 49% at 0.5 hours and further increased with time (52% at 0.75 hours, 75% at 1 hour) (Figures 4C, D). At a specificity of ≥90%, sensitivity was high and further increased with time, reaching 81% at 1 hour. We also considered the performance of the Excivion Dengue RDT in the context of DENV seroprevalence in 9-year-old children in Nicaragua, which dropped from 86.6% in 2004 to 32.2% by 2015 (30). When seroprevalence was high, PPV was high (100%), but NPV was lower across timepoints and specificities (29%-68%). When seroprevalence was lower, PPV

**TABLE 2 | Preliminary evaluation of the Excivion Dengue RDT to classify acute and early convalescent DENV and ZIKV infection samples.**

| Sample ID | Sample confirmation | Infection history | DENV RDT score | ZIKV PRNT 90 | DENV Neut titer |
|-----------|---------------------|------------------|----------------|--------------|----------------|
| 28523     | NHS                 | Naïve            | 0              | <10          | <20<sup>a</sup>|
| 28896     | NHS                 | Naïve            | 0              | <10          | <20<sup>a</sup>|
| 28897     | NHS                 | Naïve            | 0              | <10          | <20<sup>a</sup>|
| 28902     | NHS                 | Naïve            | 0              | <10          | <20<sup>a</sup>|
| 1183      | PCR-/DENV ELISA-    | Naïve            | 0              | ND           | ND             |
| 1184      | PCR-/DENV ELISA-    | Naïve            | 0              | ND           | ND             |
| 1208      | PCR-/DENV ELISA-    | Naïve            | 0              | ND           | ND             |
| 1213      | PCR-/DENV ELISA-    | Naïve            | 0              | ND           | ND             |
| 1214      | PCR-/DENV ELISA-    | Naïve            | 0              | ND           | ND             |
| PT1-2017  | PCR ND/PRNT+        | ZIKV+            | 0              | 160          | <10            |
| 778       | PCR-/PRINT+         | ZIKV+            | 0              | 78           | <10            |
| 530       | PCR-/PRINT+         | ZIKV+            | 0              | 266          | <10            |
| 574       | PCR-/PRINT+         | DENV+ZIKV+       | 0              | 358          | 10             |
| 970       | PCR-/PRINT+         | DENV+ZIKV+       | 1              | 217          | >80            |
| 389       | PCR-/PRINT+         | DENV+ZIKV+       | 1.5            | 25           | >80            |
| 29430     | NHS                 | DENV+ZIKV+       | 2              | 20           | 320<sup>a</sup>|
| 555       | PCR-/PRINT+         | DENV+ZIKV+       | 3              | 118          | >80            |
| 375       | PCR-/PRINT+         | DENV+ZIKV+       | 3.5            | 214          | >80            |
| 1136      | PCR-/PRINT+         | DENV+ZIKV+       | 4              | 40           | >80            |
| 6219c     | DEN1                | DENV+ZIKV+       | 4              | >320         | 10240<sup>a</sup>|
| 21203c    | DEN1                | DENV+ZIKV+       | 4.5            | 10           | 5120<sup>a</sup>|
| FP04237   | DEN2                | DENV+ZIKV+       | 4.5            | 10           | 40960<sup>a</sup>|
| FP05679   | DEN2                | DENV+ZIKV+       | 4.5            | 10           | 81920<sup>a</sup>|
| FP05163   | DEN2                | DENV+ZIKV+       | 4.5            | 20           | 81920<sup>a</sup>|
| 1184c     | DEN1                | DENV+ZIKV+       | 4.5            | 80           | 10240<sup>a</sup>|
| 618       | PCR-/PRINT+         | DENV+ZIKV+       | 4.5            | 492          | >80            |
| FP10111   | DEN2                | DENV+            | 5              | <10          | 20480<sup>a</sup>|
| 6720c     | DEN1                | DENV+            | 5              | 40           | 10240<sup>a</sup>|
| 21702c    | DEN1                | DENV+            | 5              | 80           | 20480<sup>a</sup>|
| FP101014  | DEN2                | DENV+ZIKV+       | 5              | >80          | >162840<sup>a</sup>|

*Sensitivity 17/18 (94%)
Specificity 12/12 (100%)

<sup>a</sup>DENV microneutralization test, otherwise DENV2-4 PRNT<sub>90</sub>
and NPV values remained the same when specificity was set to ≥98%, but PPV dropped (<85%) while NPV rose (84-91%) at specificities ≥90% (Figure S2-B). Overall, the Excivion Dengue RDT had lower than ideal specificity when evaluated visually but was able to achieve high sensitivity, including when evaluated quantitatively and when requiring high specificity.

We further evaluated the Excivion Dengue RDT in a cohort of healthy eight-year-old children participating in the ECUAVIDA cohort in Esmeraldas, Ecuador. The cohort is representative of the population where Dengvaxia might be used, with seroprevalence of 64-67%. Because no gold-standard assays were available, DENV seropositivity was measured using the Abcam dengue ELISA, while ZIKV positivity was measured using the Abcam ZIKV ELISA. When evaluated quantitatively and at a specificity of ≥90%, the Excivion dengue RDT had a sensitivity of 64%, while at a specificity of ≥98%, sensitivity was 38% (Figure 5). However, at ≥98% specificity, PPV was 97% and NPV 72%, surpassing the PPV recommended by GDAC (Figure S2-C). Overall, the Excivion Dengue RDT had lower than ideal sensitivity when detecting remote prior DENV infections but had high PPV and NPV within the seroprevalence context of this cohort.

Excivion Zika RDT

Individuals with primary ZIKV immunity are at increased risk of future symptomatic and severe dengue disease (17). However, it is not yet known whether individuals with primary ZIKV immunity and no prior DENV infection will benefit from DENV vaccination, as it is possible that Dengvaxia could further increase their future risk of severe dengue (32). Because dengue RDTs can be affected by cross-reactive immunity induced by ZIKV, for DENV-ambiguous results, it may be valuable to simultaneously test for ZIKV-specific antibodies using a separate assay. We evaluated the Excivion Zika RDT, which uses a similar design to the Excivion Dengue RDT, with sera from children with well-characterized prior ZIKV and DENV infections in the same pediatric studies in Managua, Nicaragua. When the Excivion Zika RDT was evaluated visually at 0.5 hours, 3/10 samples classified as having prior DENV infections were positive by the Excivion Zika RDT, for a specificity of 70% (Figure 6A). However, all 30/30 samples classified as ZIKV-positive were positive by the Excivion Zika RDT, with a sensitivity of 100% (Figure 6B). When evaluated quantitatively, sensitivity increased from 93% at 0.5 hours to 100% at 1 hour (Figure 6D) while maintaining optimal (≥98%) specificity (Figures 6C, D). At minimum specificity (≥90%), sensitivity was perfect at all timepoints (100%).

**DISCUSSION**

Currently, there is not a licensed assay that can quickly, easily, and accurately measure DENV immunity in the context of a mass vaccination program. In this study, we evaluate the performance of the SD BIOLINE Dengue IgG/IgM RDT to detect remote prior DENV infections using non-endemic and endemic samples. We also provide the first report of dengue and Zika RDTs developed by Excivion, present their novel design, and evaluate their performance. To try to improve sensitivity and specificity, we further analyzed the effect of developing RDTs for longer than the recommended time and evaluating RDT positivity using quantitative readers. We found that when RDTs were evaluated visually and developed for longer periods of time, increases in sensitivity were offset by decreases in specificity. In contrast, with quantitative evaluation, specificity values meeting the GDAC criteria (≥98% or ≥90%) could be ensured while also achieving higher sensitivity for detecting endemic samples for all three RDTs studied.

Most existing dengue RDTs were designed to detect acute and recent DENV infections in symptomatic patients and thus are calibrated to facilitate disease diagnosis in populations with high prevalence of anti-DENV immunity. Using samples from both endemic and non-endemic areas, we found that an existing dengue RDT, the SD BIOLINE Dengue IgG/IgM RDT, performed poorly...
when used as a screening assay for DENV serostatus in healthy subjects. The RDT was highly specific (100%) when used as directed (0.25 hours, visually) but had low sensitivity (41%) for detecting DENV seropositivity in endemic samples and even lower sensitivity for detecting primary DENV immunity in endemic samples (16%) and primary or secondary DENV immunity in non-endemic samples (0%). If the SD BIOLINE Dengue IgG/IgM RDT were used as directed, individuals with primary DENV immunity, who are at high risk of future dengue disease and may benefit most from vaccination, would rarely test positive and receive the vaccine (6, 33). When the SD BIOLINE Dengue IgG/IgM RDT was developed up to 3 hours and evaluated visually, sensitivity increased with time at the expense of specificity. Because DENV vaccinations are earmarked for seropositive children in endemic areas, the inherent trade-off between sensitivity and specificity suggests that visual evaluation of the SD BIOLINE Dengue IgG/IgM RDT in endemic settings should be limited to earlier timepoints (before 0.5 hours). However, when tests were evaluated quantitatively,
specifity could be set to ≥98% and still reach higher sensitivity (57%) at 0.25 hours, demonstrating the potential value of using RDT readers to maximize detection of DENV-seropositive individuals.

Aware of the drawbacks of current dengue RDTs, Excivion designed dengue and Zika RDTs to increase sensitivity and reduce cross-reactivity to other flaviviruses. Excivion aimed to eliminate recognition of the cross-reactive fusion loop and used preabsorption with excess off-target antigen to reduce noise from cross-reactive epitopes outside the fusion loop. In preliminary studies, we showed the Excivion Dengue RDT had high sensitivity (>94%) and specificity (100%) for detecting acute and early convalescent DENV- and ZIKV-positive samples. When visually evaluated with samples from children living in DENV and ZIKV-endemic Nicaragua and Ecuador with remote prior DENV infections, sensitivity and specificity values were equivalent, at 79%. However, quantitative evaluation of the Excivion Dengue RDT enabled prioritization of specificity, and when specificity was set to ≥98%, sensitivity was high (49%) and further increased over time. This observation suggests that alternative cutoff values may make this assay a strong candidate for pre-vaccination screening assay, among the set of assays currently available. Further, use of quantitative RDT readers developed for a smartphone or tablet could further aid in improving the performance of this and other assays, making RDTs more like an ELISA in low resource settings (34). We also observed that the Excivion Dengue RDT had high PPV (>97%) in high DENV seroprevalence settings, although in low DENV seroprevalence settings, PPV dipped below target levels (<85%) when specificity was set only to ≥90%, as is expected (12, 13). These observations further underscore the importance of prioritizing high specificity for pre-vaccination screening assays, as population seroprevalence is dynamic and can fluctuate over time.

It is not yet known whether individuals with primary ZIKV immunity and no prior DENV infection will benefit from DENV
vaccination, as it is possible that Dengvaxia or other upcoming dengue vaccines could increase future risk of severe dengue disease in this group (26, 32). We found the Excivion Zika RDT sensitivity was high (100%) at all timepoints when evaluated qualitatively but specificity was low (70%). However, sensitivity was high (>93%) and increased with time when evaluated quantitatively while keeping optimal specificity (≥98%). Because the performance of dengue RDTs can be affected by cross-reactive immunity induced by ZIKV, these results demonstrate a potential added value of additional testing with a Zika RDT, which could help identify those with only prior ZIKV immunity.

Our study has limitations. While many of our analyses of RDT sensitivity and specificity were compared to gold-standard assays (RT-PCR and/or neutralization assay), the EcoDess and ECUAVIDA cohorts were limited to classification of serostatus by the PanBio or Abcam Indirect IgG ELISA. A recent study comparing the PanBio dengue IgG ELISA to the FRNT found high correspondence, with a specificity of 93% and sensitivity of 95% for detecting DENV serostatus in a pediatric cohort in the Philippines (19). Thus, while a small proportion of the samples in the EcoDess and ECUAVIDA cohorts were likely misclassified, these studies were included because they are representative of the target populations for dengue vaccination and enabled estimation of seroprevalence, making it possible to calculate PPV and NPV.

Overall, our evaluation of the SD BIOLINE Dengue IgG/IgM RDT and first report of the novel Excivion dengue and Zika RDTs reveal that modifications to these assays can enable them to meet some but not all of the performance criteria set for dengue pre-vaccination assays. The modifications that we tested, including use of unique antigens/epitope targets in the Excivion RDTs, extension of RDT development time, and application of quantitative readers, show promise, improving sensitivity while maintaining high specificity, but likely require further optimization prior to use in dengue vaccination efforts. The development of better dengue RDTs remains a high priority for the currently licensed dengue vaccine and may be important for future dengue vaccination efforts.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

Oregon Health & Science University Institutional Review Board (IRB# 10212) approved the study protocol for the Oregon resident DENV immune cohort. IRBs of the University of Michigan and the Universidad San Francisco de Quito approved the study protocol for the EcoDess Study. The NIDDL and NMRC worked with deidentified clinical samples and a serum panel under approved human use protocol #: PJT-17-06 from NAMRU-2 and NAMRU-6. IRBs of the Hospital Pedro Vicente Maldonado and the Universidad San Francisco de Quito approved the study protocol for the ECUAVIDA Study. The Nicaragua Pediatric Dengue Cohort Study was reviewed and approved by the institutional review boards of the University of California, Berkeley (protocol: 2010-09-2245), the University of Michigan (study ID: HUM00091606), and the Nicaraguan Ministry of Health (protocol NIC-MINSA/CNDR CIRE-09/03/07-008). The Pediatric Dengue Hospital-based Study was reviewed and approved by the institutional review boards of the University of California, Berkeley (protocol 2010-06-1649) and the Nicaraguan Ministry of Health (protocol NIC-MINSA/CNDR CIRE-01/10/06-13). Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

LK, FE, JC, EH, and PL conceived the project. PL, AH, IL, ACh, and NM developed the Excivion dengue and Zika RDTs. SH, EH, FC, MM, VS, H-WC, S-JW, MS, AL, and PC performed evaluation of the Excivion RDTs. SM, LK, SV, GT, JE, WM, JC, and ACo evaluated the SD BIOLINE RDT. FE and LK analyzed the data and wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (FE, LK), and National Institutes of Health (NIH) grants (R01AI132372-02, to JE, JC), R21AI135537-02 (to WM), P01AI106695 (to EH), and contracts ‘972224’ and ‘971509’ from the UK Government via Innovate UK to Excivion Ltd under the “New Vaccines for Global Epidemics: Development and Manufacture” competition. LK was also supported by the National Center for Advancing Translational Science CTSA UL1 TR000128, Oregon Clinical and Translational Research Institute, Takeda Vaccines ISIR 2016-101586, and the Sunlin and Priscilla Chou Foundation.

ACKNOWLEDGMENTS

We thank the study participants and their families.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.703887/full#supplementary-material

Supplementary Figure 1 | Evaluation of the IgG component of the SD BIOLINE Dengue IgG/IgM rapid diagnostic test, stratified by primary DENV infecting serotype, for samples from the Oregon traveler cohort. Columns indicate infecting serotype, top row shows visual evaluations, and bottom row shows quantitative readings.
Supplementary Figure 2 | Positive predictive value and negative predictive value estimates for the EcoDess, Nicaragua, and ECUAVIDA cohorts. Positive predictive values and negative predictive values using optimal ≥98% specificity (PPV; light orange dots, NPV; blue squares) and minimum >90% specificity (PPV; dark orange dots, NPV; navy blue squares) at distinct timepoints for the EcoDess (A), Nicaragua (using seroprevalence estimates from both 2004 and 2015) (B), and ECUAVIDA (C) cohorts. Smoothing splines and simple linear regressions show trends over time for the EcoDess and Nicaragua cohorts respectively.

Supplementary Figure 3 | Evaluation of the Exciven Dengue IgG rapid diagnostic test by primary and secondary DENV infecting serotype in samples from the Nicaragua Pedigree Dengue Cohort and Hospital-based Studies. Columns indicate infecting serotype. Top row shows visual evaluations, and bottom row shows quantitative readings.

REFERENCES

1. Cattarino L, Rodriguez-Barruaquer I, Imai N, Cummings DAT, Ferguson NM. Mapping Global Variation in Dengue Transmission Intensity. Sci Transl Med (2020) 12:eaxaa444. doi: 10.1126/scitranslmed.aaxaa444
2. World Health Organization. Dengue Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition. (Geneva, Switzerland 2009), WHO/HTM/NDEN/2009.1.
3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The Global Distribution and Burden of Dengue. Nature (2013) 496:504–7. doi: 10.1038/nature12060
4. L’Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel TA, et al. Symptomatic Dengue in children in 10 Asian and Latin American Countries. New Engl J Med (2016) 374:1155–66. doi: 10.1056/NEJMoa1503877
5. Hammon WMCD, Rundnick A, Sather GE. Viruses Associated With Epidemic Hemorrhagic Fevers of the Philippines and Thailand. Science (1960) 131:1112. doi: 10.1126/science.131.3407.1102
6. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-Dependent Enhancement of Severe Dengue Disease in Humans. Science (2017) 358:929. doi: 10.1126/science.aan6836
7. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongs S, Jatanasen S, Salitul V, et al. Risk Factors in Dengue Shock Syndrome: A Prospective Epidemiologic Study in Rayong, Thailand: I. The 1980 Outbreak. Am J Epidemiol (1984) 120:63–69. doi: 10.1093/oxfordjournals.aje.a113932
8. Olkowski S, Forshey BM, Morrison AC, Rocha C, Villarromero S, Halsey ES, et al. Reduced Risk of Disease During Postsecondary Dengue Virus Infections. J Infect Dis (2013) 208:1026–33. doi: 10.1093/infdis/jit273
9. Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, et al. A New Class of Highly Potent, Broadly Neutralizing Antibodies Isolated From Viremic Patients Infected With Dengue Virus. Nat Immunol (2015) 16:170–7. doi: 10.1038/ni.3058
10. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. New Engl J Med (2018) 379:327–40. doi: 10.1056/NEJMoa1800820
11. Dengue Vaccine: WHO Position Paper, September 2018 – Recommendations. Vaccine (2019) 37:4848–57. doi: 10.1016/j.vaccine.2018.09.063
12. Wilder-Smith A, Smith PG, Luo R, Kelly-Cirino C, Curry D, Larson H, et al. Pre-Vaccination Screening Strategies for the Use of the CYD-TDV Dengue Vaccine: A Meeting Report. Vaccine (2019) 37:5137–46. doi: 10.1016/ j.vaccine.2019.07.016
13. Rodriguez-Barruaquer I, Salje H, Cummings DAT. Dengue Pre-Vaccination Screening and Positive Predictive Values. Lancet Infect Dis (2019) 19:132–4. doi: 10.1016/S1473-3099(18)30799-0
14. Bonaparte M, Zheng L, Garg S, Guy B, Lustig Y, Schwartz E, et al. Evaluation of Rapid Diagnostic Tests and Conventional Enzyme-Linked Immunoblot Assays to Determine Prior Dengue Infection. J Travel Med (2019) 26(8):taa078. doi: 10.1093/ttm/taa078
15. Siroti D, Chen Z, Sun L, Klose T, Pierson TC, Rossmann MG, et al. The 3.8 Å Resolution Cryo-EM Structure of Zika Virus. Science (2016) 352:467. doi: 10.1126/science.aaf3516
16. King AMQ, Adams MJ, Carstens EB. “Family - Flaviviridae”. In: JE Letkowitz, editor. Virus Taxonomy. San Diego: Elsevier (2012). p. 1003–20. doi: 10.1016/B978-0-12-384684-6.00086-0
17. Katzelnick LC, Narvaez C, Arguelles S, Lopez Mercado B, Collado D, Ampie O, et al. Zika Virus Infection Enhances Future Risk of Severe Dengue Disease. Science (2020) 369:1123. doi: 10.1126/science.abc66143
18. Khosavanna RR, Kareko BW, Brady AC, Booty BL, Nix CD, Lyski ZL, et al. Clinical Symptoms of Dengue Infection Among Patients From a Non-Endemic Area and Potential for a Predictive Model: A Multiple Logistic Regression Analysis and Decision Tree. Am J Trop Med Hyg (2021) 104:121–9. doi: 10.4269/ajtmh.20-0192
19. Lopez AL, Adams C, Ylade M, Jardi R, Daag JV, Molloy CT, et al. Determining Dengue Virus Serostatus by Indirect IgG ELISA Compared With Focus Reduction Neutralisation Test in Children in Cebu, Philippines: A Prospectivce Population-Based Study. Lancet Global Health (2021) 9:e44–51. doi: 10.1016/S2214-109X(20)30392-2
20. Balsaseda A, Stettler K, Medina-Carrera R, Collado D, Jin X, Zambrana JV, et al. Antibody-Based Assay Discriminates Zika Virus Infection From Other Flaviviruses. Proc Natl Acad Sci (2017) 114(31):8384–89. doi: 10.1073/pnas.1704984114
21. Pau G, Fuchs F, Sklyar O, Boutros M, Huber W. EBImage—An R Package for Image Processing With Applications to Cellular Phenotypes. Bioinformatics (2010) 26:979–81. doi: 10.1093/bioinformatics/btp046
22. Williams M, Ewing D, Blevins M, Sun P, Sundaram AK, Raviprakash KS, et al. Enhanced Immunogenicity and Protective Efficacy of a Tetraavalent Dengue DNA Vaccine Using Electroporation and Intradermal Delivery. Vaccine (2019) 37:4444–53. doi: 10.1016/j.vaccine.2019.06.083
23. Gordon A, Gresh L, Ojeda S, Katzelnick LC, Sanchez N, Mercado JC, et al. Prior Dengue Virus Infection and Risk of Zika: A Pediatric Cohort in Nicaragua. PloS Med (2016) 16:e1002726. doi: 10.1371/journal.pmed.1002726
24. Gordon A, Kuan G, Mercado JC, Gresh L, Aviles W, Balsaseda A, et al. The Nicaraguan Pediatric Dengue Cohort Study: Incidence of Inapparent and Symptomatic Dengue Viruses, 2004–2010. PloS Neglected Trop Dis (2013) 7:e2462. doi: 10.1371/journal.pntd.0002462
25. Kuan G, Gordon A, Aviles W, Ortega O, Hammond SN, Elizondo D, et al. The Nicaraguan Pediatric Dengue Cohort Study: Study Design, Methods, Use of Information Technology, and Extension to Other Infectious Diseases. Am J Epidemiol (2009) 170:129–9. doi: 10.1093/aje/kwp092
26. Katzelnick LC, Narvaez C, Arguelles S, Lopez Mercado B, Collado D, Ampie O, et al. Zika Virus Infection Enhances Future Risk of Severe Dengue Disease. Science (2020) 369:1123. doi: 10.1126/science.abc66143
27. Narvaez F, Gutierrez G, Peñate W, Balmaseda A, et al. Antibody-Based Assay Discriminates Zika Virus Infection From Other Flaviviruses. Vaccine (2019) 37:4444–53. doi: 10.1016/j.vaccine.2019.06.083
28. Fernandez RJ, Vazquez S. Serological Diagnosis of Dengue by an Elisa Reduction Neutralization Test in Children in Cebu, Philippines: A Prospective Population-Based Study. Lancet Global Health (2021) 9:e44–51. doi: 10.1016/S2214-109X(20)30392-2
29. Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, et al. Symptomatic Versus Inapparent Outcome in Repeat Dengue Virus
Infections Is Influenced by the Time Interval Between Infections and Study Year. *PloS Neglected Trop Dis* (2013) 7:e2357–. doi: 10.1371/journal.pntd.0002357

30. Katzelnick LC, Ben-Shachar R, Mercado JC, Rodriguez-Barraquer I, Elizondo D, Arguello S, et al. Dynamics and Determinants of the Force of Infection of Dengue Virus From 1994 to 2015 in Managua, Nicaragua. *Proc Natl Acad Sci* (2018) 115:10762. doi: 10.1073/pnas.1809253115

31. Chis Ster I, Rodriguez A, Romero NC, Lopez A, Chico M, Montgomery J, et al. Age-Dependent Seroprevalence of Dengue and Chikungunya: Inference From a Cross-Sectional Analysis in Esmeraldas Province in Coastal Ecuador. *BMJ Open* (2020) 10:e040735–e040735. doi: 10.1136/bmjopen-2020-040735

32. RE: Vaccine Implications of Prior Zika Virus Infection Enhancement of Subsequent Dengue Infection | *Science*. Available at: https://science.sciencemag.org/content/re-vaccine-implications-prior-zika-virus-infection-enhancement-subsequent-dengue-infection (Accessed March 14, 2021).

33. Salje H, Cummings DAT, Rodriguez-Barraquer I, Katzelnick LC, Lessler J, Klungthong C, et al. Reconstruction of Antibody Dynamics and Infection Histories to Evaluate Dengue Risk. *Nature* (2018) 557:719–23. doi: 10.1038/s41586-018-0157-4

34. Mudanyali O, Dimitrov S, Sikora U, Padmanabhan S, Navruz I, Ozcan A. Integrated Rapid-Diagnostic-Test Reader Platform on a Cellphone. *Lab Chip* (2012) 12:2678–86. doi: 10.1039/C2LC40235A

Conflict of Interest: Authors PL and AH were employed by company Excivion Ltd. PL and AH hold stock in Excivion Ltd and via Excivion Ltd hold stock in Coronex Ltd, which companies own patent applications in RDTs and vaccines. AC was employed by company Oxford Expression Technologies Ltd. NM was employed by company GlobalDX Ltd. IL has acted as a consultant for Excivion Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Echegaray, Laing, Hernandez, Marquez, Harris, Laing, Chambers, McLennan, Sugiharto, Chen, Villagran, Collingwood, Montoya, Carrillo, Simons, Cooper, Lopez, Trueba, Eisenberg, Wu, Messer, Harris, Coloma and Katzelnick. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.